1-(2-Chloro-4-(4-chlorophenyl)butyl)-1H-imidazole: Your Partner in Antifungal Drug Development
The journey from laboratory research to a market-ready pharmaceutical product is complex, with chemical intermediates playing a pivotal role at every stage. For companies developing antifungal medications, understanding and reliably sourcing key intermediates is essential. 1-(2-Chloro-4-(4-chlorophenyl)butyl)-1H-imidazole (CAS: 67085-12-5) stands out as a crucial component, primarily for its role in the synthesis of the antifungal agent, butoconazole.
Chemical Profile and Synthetic Importance
This chemical intermediate, represented by the molecular formula C13H14Cl2N2, typically presents as a white powder. Its significance in drug development lies in its specific chemical structure and high purity, often supplied with an assay of u226598.0%. This purity is critical for ensuring that the subsequent chemical reactions proceed efficiently, leading to the formation of the desired API with minimal impurities. The precision in its synthesis directly translates to the quality of the final pharmaceutical product.
Manufacturers and researchers utilize 1-(2-Chloro-4-(4-chlorophenyl)butyl)-1H-imidazole not only as a direct precursor but also as a benchmark in quality control. Its presence as a potential impurity in the final butoconazole product means that well-characterized batches are indispensable for developing and validating analytical methods. This diligence ensures that the marketed antifungal drugs meet the highest safety and efficacy standards.
Sourcing Strategies for Pharmaceutical Innovation
For research scientists and procurement specialists, identifying dependable suppliers is paramount when looking to buy this intermediate. Companies specializing in pharmaceutical intermediates, particularly those with a strong presence in chemical manufacturing hubs like China, offer a valuable resource. When considering a supplier, it's important to look for:
- Commitment to Quality: Suppliers who provide detailed Certificates of Analysis (CoAs) and adhere to strict quality control measures are essential.
- Technical Expertise: A supplier with a strong understanding of pharmaceutical intermediates can offer valuable support during the development process.
- Reliable Supply Chain: Consistent availability and timely delivery are crucial for uninterrupted research and manufacturing.
- Competitive Pricing: Balancing quality with cost-effectiveness is key for optimizing development budgets.
Engaging with a reputable manufacturer not only ensures the quality of the intermediate but also facilitates smooth project progression. Whether for early-stage research or large-scale production, securing a reliable source for 1-(2-Chloro-4-(4-chlorophenyl)butyl)-1H-imidazole is a strategic move.
Conclusion: A Cornerstone for Antifungal Therapies
In summary, 1-(2-Chloro-4-(4-chlorophenyl)butyl)-1H-imidazole is more than just a chemical compound; it is a critical enabler of antifungal drug development. Its purity and reliable availability from qualified manufacturers are fundamental to producing safe and effective medications. Pharmaceutical companies seeking to buy this essential intermediate should prioritize suppliers who demonstrate a commitment to quality and a deep understanding of the pharmaceutical supply chain.
Explore your procurement options and partner with a supplier who can reliably provide this vital compound, supporting your mission to deliver effective antifungal solutions to the market.
Perspectives & Insights
Alpha Spark Labs
“Engaging with a reputable manufacturer not only ensures the quality of the intermediate but also facilitates smooth project progression.”
Future Pioneer 88
“Whether for early-stage research or large-scale production, securing a reliable source for 1-(2-Chloro-4-(4-chlorophenyl)butyl)-1H-imidazole is a strategic move.”
Core Explorer Pro
“Conclusion: A Cornerstone for Antifungal TherapiesIn summary, 1-(2-Chloro-4-(4-chlorophenyl)butyl)-1H-imidazole is more than just a chemical compound; it is a critical enabler of antifungal drug development.”